Mechanism of Action
Our Science
Our Advanced Engineering Created Vectors
That Are Precise, Potent and Safe
That Are Precise, Potent and Safe
Publications
-
Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12
-
1998P: Preliminary Results From a Phase l study of T3011, an Oncolytic HSV Expressing lL-12 and Anti-PD-1Antibody, for BCG-Failure Non-Muscle-Invasive Bladder Cancer
-
Advanced glioblastoma immunotherapy: Attenuated herpes oncolytic virus armed with anti-PD-1 antibodv and lL-12
-
Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
-
Non-clinical studies of systemic delivery of oncolytic virus arms with IL-12 and anti-PD-1 antibody
-
New generation of oncolytic herpesviruses embodying immunotherapeutic genes encoding IL-12 and anti-PD-1 antibody
-
A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies
-
New generation of oncolytic herpesviruses embodying immunotherapeutic genes encoding IL-12 and anti-PD-1 antibody
-
Enhancement of Oncolytic Activity of oHSV Expressing IL-12 and Anti-PD-1 Antibody by Concurrent Administration of Exosomes Carrying CTLA-4 MiRNA
-
Topical application of genetically engineered exosomes offers a non-invasive approach to localized fat reduction
-
Subcutaneous injection of genetically engineered exosomes for androgenic alopecia treatment
-
MiR-H28 and miR-H29 expressed late in productive infection are exported and restrict HSV-1 replication and spread in recipient cells
-
Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity
-
MiRNAs Targeting ICP4 and Delivered to Susceptible Cells in Exosomes Block HSV-1 Replication in a Dose-Dependent Manner
